AI Article Synopsis
Article Abstract
Background: Neutrophil NETosis and neutrophil extracellular traps (NETs) play a critical role in pathogenesis of coronavirus disease 2019 (COVID-19)-associated thrombosis. However, the extents and reserve of NETosis, and potential of thrombus formation under shear in whole blood of patients with COVID-19 are not fully elucidated. Neither has the role of recombinant ADAMTS13 or caplacizumab on the accumulation of NETs and thrombus in COVID-19 patients' whole blood under shear been investigated.
Methods: Flow cytometry and microfluidic assay, as well as immunoassays, were employed for the study.
Results: We demonstrated that the percentage of H3Cit + MPO+ neutrophils, indicative of NETosis, was dramatically increased in patients with severe but not critical COVID-19 compared with that in asymptomatic or mild disease controls. Upon stimulation with poly [I:C], a double strain DNA mimicking viral infection, or bacterial shigatoxin-2, the percentage of H3Cit + MPO+ neutrophils was not significantly increased in the whole blood of severe and critical COVID-19 patients compared with that of asymptomatic controls, suggesting the reduction in NETosis reserve in these patients. Microfluidic assay demonstrated that the accumulation of NETs and thrombus was significantly enhanced in the whole blood of severe/critical COVID-19 patients compared with that of asymptomatic controls. Like DNase I, recombinant ADAMTS13 or caplacizumab dramatically reduced the NETs accumulation and thrombus formation under arterial shear.
Conclusion: Significantly increased neutrophil NETosis, reduced NETosis reserve, and enhanced thrombus formation under arterial shear may play a crucial role in the pathogenesis of COVID-19-associated coagulopathy. Recombinant ADAMTS13 or caplacizumab may be explored for the treatment of COVID-19-associated thrombosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11260255 | PMC |
| http://dx.doi.org/10.1055/a-2253-9359 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Thrombotic thrombocytopenic purpura with juvenile systemic lupus erythematosus: successful treatment with caplacizumab and rituximab.
Pediatr Rheumatol Online J
December 2024
Department of Pediatrics, Kanazawa University Hospital, Takara-machi 13-1, Kanazawa, 920-8640, Ishikawa, Japan.
Complex immunogenicity assessment in caplacizumab-treated patients with immune-mediated thrombotic thrombocytopenic purpura who have received plasma exchange.
Res Pract Thromb Haemost
November 2024
Sanofi, Ghent, Belgium.
Background: International Society on Thrombosis and Haemostasis guidelines for immune-mediated thrombotic thrombocytopenic purpura (iTTP) treatment recommend concurrent therapeutic plasma exchange (TPE), immunosuppressive therapy (IST), and caplacizumab. TPE can complicate antidrug antibody (ADA) measurements by transferring pre-existing antibodies (pre-Abs) into patients via donor plasma and/or diluting treatment-emergent (TE) ADAs.
Objectives: To assess the presence of ADAs in patients with iTTP who received caplacizumab.
Real-World Data on Effectiveness and Safety of First-Line Use of Caplacizumab in Italian Centers for the Treatment of Thrombotic Thrombocytopenic Purpura: The Roscapli Study.
J Clin Med
October 2024
Service of Haemorrhagic and Thrombotic Diseases, Fondazione Policlinico Universitario Agostino Gemelli-IRCCS, 00168 Rome, Italy.
: Immune thrombotic thrombocytopenic purpura (iTTP) is a thrombotic microangiopathy caused by the formation of anti-ADAMTS13 antibodies. Caplacizumab is approved for the treatment of acute episodes of iTTP in conjunction with plasma exchange (PEX) and immunosuppression. Real-world data for the use of caplacizumab in Italy have been recently published by a limited number of centers located in the northern and middle regions of the country only.
View Article and Find Full Text PDF[100 years thrombotic thrombocytopenic purpura (TTP) - lessons learned?].
Dtsch Med Wochenschr
November 2024
Klinik für Innere Medizin I - Abteilung für Hämatologie und Hämostaseologie, Medizinische Universität Wien, Österreich.
100 years ago Dr. Eli Moschcowitz described the first case of thrombotic thrombocytopenic purpura. For many decades there were no recognized treatment options, and the mortality rate was extremely high.
View Article and Find Full Text PDFVitamin B12 Deficiency in Thrombotic Thrombocytopenic Purpura-Like Cases.
Eur J Case Rep Intern Med
September 2024
Hematology and Oncology, University Cancer & Blood Center, Athens, USA.
Article Synopsis
- Thrombotic microangiopathies (TMA) involve a combination of hemolytic anemia, low platelet counts, and organ damage typically stemming from endothelial damage, but vitamin B12 deficiency can mimic this condition.
- A 60-year-old woman presented with signs of severe illness, leading to a high-risk diagnosis of thrombotic thrombocytopenic purpura (TTP), but was later found to have a significant vitamin B12 deficiency, which explained her symptoms.
- This case emphasizes that vitamin B12 deficiency can present like TTP, and clinicians should consider it as a potential cause of microangiopathic hemolytic anemia when specific lab results indicate low B12 levels and low reticulocyte counts, enabling
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!